Trevi Therapeutics Inc (NASDAQ:TRVI) has a beta value of 0.41 and has seen 1.07 million shares traded in the recent trading session. The company, currently valued at $584.93M, closed the recent trade at $6.05 per share which meant it lost -$0.24 on the day or -3.82% during that session. The TRVI stock price is -22.15% off its 52-week high price of $7.39 and 61.98% above the 52-week low of $2.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.7 million shares traded. The 3-month trading volume is 1.97 million shares.
The consensus among analysts is that Trevi Therapeutics Inc (TRVI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.12.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Sporting -3.82% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TRVI stock price touched $6.05 or saw a rise of 9.57%. Year-to-date, Trevi Therapeutics Inc shares have moved 46.84%, while the 5-day performance has seen it change -8.47%. Over the past 30 days, the shares of Trevi Therapeutics Inc (NASDAQ:TRVI) have changed 42.02%. Short interest in the company has seen 4.68 million shares shorted with days to cover at 1.11.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could drop -0.83% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is 0.83% off the targeted high while a plunge would see the stock lose 0.83% from the levels at last check today.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
The company’s shares have gained 81.68% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 27.09% over the past 5 years. Earnings growth for 2025 is a modest -11.80% while over the next 5 years, the company’s earnings are expected to decrease by -15.10%.
TRVI Dividends
Trevi Therapeutics Inc is expected to release its next earnings report on 2025-Mar-17 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
Insiders own 0.90% of the company shares, while shares held by institutions stand at 86.28% with a share float percentage of 87.06%. Investors are also buoyed by the number of investors in a company, with Trevi Therapeutics Inc having a total of 143.0 institutions that hold shares in the company. The top two institutional holders are NEA MANAGEMENT COMPANY, LLC with over 11.37 million shares worth more than $33.88 million. As of 2024-06-30, NEA MANAGEMENT COMPANY, LLC held 11.2532% of shares outstanding.
The other major institutional holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., with the holding of over 7.38 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.0 million and represent 7.305% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.32% shares in the company for having 2.24 shares of worth $13.75 million while later fund manager owns 1.52 shares of worth $9.33 million as of Feb 28, 2025, which makes it owner of about 1.58% of company’s outstanding stock.
